Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of T-817MA in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
NL-OMON52556Phase 2Active, not recruiting
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing T-817MA with Placebo (2 arms). Primary endpoint: Change in CSF p-tau181 from Baseline to Week 78. Started Nov 2019; status: active, not recruiting.
02
Drugs
edonerpic
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NL-OMON52556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52556.